Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment

被引:88
|
作者
Swee, Lee Kim [1 ]
Bosco, Nabil [1 ]
Malissen, Bernard [2 ]
Ceredig, Rhodri [1 ,3 ]
Rolink, Antonius [1 ]
机构
[1] Univ Basel, Dept Biomed Basel, Div Mol Immunol, CH-4058 Basel, Switzerland
[2] Univ Mediterrannee, Ctr Immunol Marseille Luminy, Inserm U631, CNRS UMR 6102, Marseille, France
[3] Univ Franche Comte, Inserm U645, Etab Francais Sang, Bourgogne Franche Comte,Inst Fed Rech 133, F-25030 Besancon, France
基金
瑞士国家科学基金会;
关键词
DENDRITIC CELLS; FLT3; LIGAND; IN-VITRO; LYMPHOPROLIFERATIVE DISORDER; HEMATOPOIETIC STEM; SELF-TOLERANCE; MICE; INTERLEUKIN-2; DEFICIENT; ACTIVATION;
D O I
10.1182/blood-2008-06-161026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fms-like tyrosine kinase 3 ligand (FLT3L) plays a major role in dendritic cell (DC) biology. Deficiency of FLT3L causes a dramatic decrease in DC numbers, whereas increasing its availability (by repetitive injections for 7-10 days) leads to a 10-fold increase in DC numbers. In this study, we show that FLT3L treatment indirectly leads to an expansion of peripheral naturally occurring T regulatory cells (NTregs). The FLT3L-induced increase in NTregs was still observed in thymectomized mice, ruling out the role of the thymus in this mechanism. Instead, the increased number of NTregs was due to proliferation of preexisting NTregs, most likely due to favored interactions with increased number of DCs. In vitro, we show that DCs induce regulatory T-cell (Treg) proliferation by direct cell contact and in an interleukin-2-dependent, T-cell receptor-independent manner. FLT3L could prevent death induced by acute graft-versus-host disease (GVHD). This study demonstrates unique aspects in the regulation of Treg homeostasis by DCs, which were unappreciated until now. It also reinforces the relevance of FLT3L treatment in GVHD by its ability to increase both the number of tolerizing DCs and NTregs. (Blood. 2009; 113: 6277-6287)
引用
收藏
页码:6277 / 6287
页数:11
相关论文
共 50 条
  • [1] Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
    Svensson, Mattias N. D.
    Andersson, Sofia E. M.
    Erlandsson, Malin C.
    Jonsson, Ing-Marie
    Ekwall, Anna-Karin H.
    Andersson, Karin M. E.
    Nilsson, Anders
    Bian, Li
    Brisslert, Mikael
    Bokarewa, Maria I.
    PLOS ONE, 2013, 8 (01):
  • [2] Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation
    Shao, Zhifei
    Bharadwaj, Arpita S.
    McGee, Halvor S.
    Makinde, Toluwalope O.
    Agrawal, Devendra K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (04) : 917 - 924
  • [3] FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
    Ghali, Joanna R.
    O'Sullivan, Kim M.
    Eggenhuizen, Peter J.
    Holdsworth, Stephen R.
    Kitching, A. Richard
    PLOS ONE, 2015, 10 (04):
  • [4] Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation
    Ramos, M. I.
    Tak, P. P.
    Lebre, M. C.
    AUTOIMMUNITY REVIEWS, 2014, 13 (02) : 117 - 124
  • [5] In vivo administration of Fms-like tyrosine kinase-3 ligand effectively stimulates lung dendritic cell expansion in mice
    Wang Hong-wei
    Lu Jiang-yang
    Wang Lin
    Tian Guang
    CHINESE MEDICAL JOURNAL, 2012, 125 (14) : 2562 - 2567
  • [6] Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment
    Matsumura, Noriomi
    Mandai, Masaki
    Hamanishi, Junzo
    Yamaguchi, Ken
    Fukuhara, Ken
    Yagi, Haruhiko
    Higuchi, Toshihiro
    Takakura, Kenji
    Fujii, Shingo
    ONCOLOGY REPORTS, 2008, 19 (02) : 505 - 515
  • [7] Hosts lacking fms-like tyrosine kinase 3 ligand exhibit marked reductions in transplant vascular sclerosis
    Wang, ZL
    Taner, T
    Morelli, AE
    Thomson, AW
    TRANSPLANTATION, 2005, 79 (08) : 869 - 875
  • [8] FMS-Like Tyrosine Kinase 3 Ligand Treatment of Mice Aggravates Acute Lung Injury in Response to Streptococcus pneumoniae: Role of Pneumolysin
    Brumshagen, Christina
    Maus, Regina
    Bischof, Andrea
    Ueberberg, Bianca
    Bohling, Jennifer
    Osterholzer, John J.
    Ogunniyi, Abiodun D.
    Paton, James C.
    Welte, Tobias
    Maus, Ulrich A.
    INFECTION AND IMMUNITY, 2012, 80 (12) : 4281 - 4290
  • [9] Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment
    Ma, Chenchen
    Cui, Siyuan
    Xu, Ruirong
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (29) : 4657 - 4686
  • [10] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    Swords, R.
    Freeman, C.
    Giles, F.
    LEUKEMIA, 2012, 26 (10) : 2176 - 2185